

Remus Pharmaceuticals Limited reports consolidated revenue of ₹ 193.44 crores for Q1 FY 2025–26 with 46.02% growth on a YoY basis, Sustains Robust Growth Trajectory

Ahmedabad, Thursday, August 14, 2025: Remus Pharmaceuticals Limited (“**Remus**”), is pleased to voluntarily disclose its unaudited revenue performance and profit before tax (“**PBT**”) for Q1 FY 2025–26. Reporting a strong topline of **₹ 193.44 crores**, a significant increase from **₹ 132.48 crores** during the same period in FY 2024–25, reflecting a year-on-year (“**YoY**”) growth of **46.02%**.

For the quarter ended June 30, 2025, Remus clocked a consolidated PBT of **₹ 11.90 crores**, representing a significant YoY increase of **30.39%** in line with its strong revenue growth trajectory.

Momentum during the quarter was fueled by these primary drivers:

- 1. Strong execution across markets with a resilient product pipeline:** Remus has consistently delivered strong order execution across multiple geographies, including recent expansions into **Peru and El Salvador**, maintaining timely and efficient deliveries despite regional challenges. Backed by a strategically diversified product portfolio and a dedicated focus on high-growth, specialized therapeutic areas, Remus is actively broadening its presence in Oncology, Biosimilars (Monoclonal Antibodies (MABs)) and Peptides—sectors that offer substantial market potential.
- 2. A healthy pipeline of orders ensures sustained forward visibility:** With consolidated order book for **₹ 170 crores**, Remus boasts healthy and expanding operations globally, underpinned by its proven ability to execute seamlessly across diversified geographies. Leveraging its Bolivia-based subsidiary to access institutional demand, Remus is strategically diversifying its revenue streams and mitigating market-specific risks, positioning itself for long-term growth and profitability.
- 3. Building strong direct-to-consumer (D2C) and pharmacy networks:** Remus is expanding its market footprint through strategic pharmacy partnerships and focused brand-building initiatives, which have significantly enhanced market penetration and a rapidly scaling direct-to-consumer (D2C) channel poised to deliver 100% revenue growth. This well-integrated distribution model provides a strong foundation for sustained growth and reinforces the Remus’s competitive positioning across diverse geographies.

Management Comments:

Commenting on the development, Mr. Arpit Shah, Managing Director of Remus Pharmaceuticals Limited, said: “This quarter marks a strong start to the fiscal year, driven by our diversified growth engines and consistent global registration efforts. Our expanding product portfolio and robust pipeline, supported by integrated D2C and pharmacy networks, are accelerating market penetration and strengthening brand equity. We remain focused on scaling our global presence and optimizing distribution channels. With a solid foundation, we are well-positioned to sustain growth and deliver long-term value to stakeholders throughout FY 2025–26.”

About Remus Pharmaceuticals Limited:

Remus Pharmaceuticals Limited is engaged in exporting, marketing and distribution of finished formulations of pharmaceutical drugs. Having strong footprints in 40+ countries across the globe, Remus is involved in the sales of niche, specialized and critical care finished formulations. Remus is actively engaged in D2C via Pharmacy networks for speciality niche formulations through its subsidiaries in various markets.

Safe Harbor

This document includes certain forward-looking statements which are tentative, based on current expectations of the management of Remus Pharmaceuticals Limited or any of its subsidiaries ("Remus"). These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological, and/or regulatory factors, exchange rate fluctuations, cash flow projections, interest, and other costs. Remus, its directors, and any of the affiliates or employees are under no obligation to and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise. Remus does not undertake any obligation to revise or update any forward-looking statement that may be made from time to time by or on behalf of the Company including to reflect actual results, changes in assumptions or changes in factors affecting these statements.

Follow Remus Pharmaceuticals Limited on LinkedIn: <https://www.linkedin.com/company/remus-pharmaceuticals/>

Contact Information:

Investor Relations Representative: Mr. Anuj Sonpal Valorem Advisors Tel: +91-22-4903-9500 Email: remus@valoremadvisors.com	Chief Financial Officer Ms. Anjali Shah Remus Pharmaceuticals Limited Email: ir@remuspharma.com
--	---